Atossa Therapeutics Inc. (NASDAQ: ATOS) fell 4% last week. The company, which is focusing on the discovery and development of innovative drugs in oncology and infectious diseases, released a video last week recognizing Breast Cancer Awareness Month urging women to receive mammograms.
Market Action:
On Friday, ATOS stock fell 1.77% at $2.7800 with more than 3.40 million shares, compared to its average volume of 6.57 million shares. The stock has moved within a range of $2.6900 – 2.8100 after opening the trade at $2.7888.
Key Updates
In the video, the company’s CEO Dr. Steven Quay cited that the current COVID-19 pandemic has changed everything regarding breast cancer screening stating that most women have stopped going for mammograms since the start of COVID-19. The sentiment is corroborated in the Preventive Medicine journal’s October 2021 issue, which indicated that screening was a challenge, especially for women from low-income brackets and those of color.
Recently the company commenced participants recruitment in the AT-H201 clinical study in Australia. AT-H201 is a nebulized formulation the company is developing as an inhalation treatment from moderate to severe COVID-19 in hospitalized and long-haul patients with post-infection pulmonary disease. With these developments, investors should keep an eye on ATOS.
